Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Oncology
Reference11 articles.
1. Girard N (2012) Other signalization. Target Oncol (in press)
2. La Madrid AM, Campbell N, Smith S, Cohn SL, Salgia R (2012) Targeting ALK: a promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin’s lymphoma, and neuroblastoma. Target Oncol 7(3):199–210
3. Gridelli C (2012) ALK inhibitors: a new targeted therapy in the treatment of NSCLC. Target Oncol (in press)
4. Demetri GD, Reichardt P, Kang Y et al (2012) Randomized phase III trial of regorafenib in patients with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) progressing despite prior treatment with at least imatinib (IM) and sunitinib(SU): GRID trial. Proceedings of ASCO LBA 10008. J Clin Oncol 30
5. DW B, ER K, Jmeno A (2011) Multi-targeted tyrosine kinase inhibitors in clinical development: focus onXL-184 (cabozantinib). Drugs Today 47(11):857–868
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献